Kolexia
Arkam Yazid Hématologie
Arkam Yazid
Hématologie
Hôpital Emile Muller
Mulhouse, France
72 Activités
5 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Lymphome à cellules du manteau Leucémies Leucémie chronique lymphocytaire à cellules B Leucémie lymphoïde Hypoalbuminémie Macroglobulinémie de Waldenström COVID-19 Leucémie myéloïde chronique BCR-ABL positive

Collaborateurs

Voir plus
Drenou Bernard
Drenou Bernard
Hôpital Emile Muller, Mulhouse, France
Newinger Muriel
Newinger Muriel
Hôpital Emile Muller, Mulhouse, France
Eisenmann Jean-Claude
Eisenmann Jean-Claude
Hôpital Hasenrain, Mulhouse, France
Debliquis Agathe
Debliquis Agathe
Hôpital Emile Muller, Mulhouse, France

Industries

Voir plus
A+A
76 collaboration(s)
Dernière en 2022
IQVIA
54 collaboration(s)
Dernière en 2023
B3TSI
51 collaboration(s)
Dernière en 2023
Ipsos Mori UK Limited
13 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
Dutcher bodies in a Waldenström Macroglobulinaemia patient.
Annales de biologie clinique   26 février 2024
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Haematologica   30 novembre 2023
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in elderly mantle cell lymphoma patients. For the LYSA group.
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023   09 juin 2023
Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim
Annual Meeting Abstracts 2022   15 novembre 2022
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
Leukemia   22 janvier 2021
Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
American journal of hematology   25 août 2020
Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study.
Leukemia & lymphoma   09 janvier 2019
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.
Haematologica   31 août 2018
Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study.
Leukemia & lymphoma   09 février 2017
How to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients : Results on 86 Patients of the French BPDCN Network
Blood   03 décembre 2015